Expression and Cellular Localization of Follicle-Stimulating Hormone Receptor in Normal Human Prostate, Benign Prostatic Hyperplasia and Prostate Cancer-Reference-Cited by-同舟云学术

Expression and Cellular Localization of Follicle-Stimulating Hormone Receptor in Normal Human Prostate, Benign Prostatic Hyperplasia and Prostate Cancer

Published:2006-06 Issue:6 Volume:175 Page:2072-2077
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Mariani Stefania¹,Salvatori Luisa²³,Basciani Sabrina¹,Arizzi Mario¹,Franco Giorgio⁴,Petrangeli Elisa²³,Spera Giovanni¹,Gnessi Lucio¹

Affiliation:

1. Department of Medical Pathophysiology, University of Rome “La Sapienza”, Rome, Italy

2. Department of Experimental Medicine and Pathology, University of Rome “La Sapienza”, Rome, Italy

3. National Research Council, Institute of Molecular Biology and Pathology, Rome, Italy

4. Department of Urology, University of Rome “La Sapienza”, Rome, Italy

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference22 articles.

1. Prevalence-corrected prostate cancer incidence rates and trends;Merrill;Am J Epidemiol,2002

2. Survival in prostate carcinoma: outcomes from a prospective, population-based cohort of 8,887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden;Aus;Cancer,2005

3. Molecular genetics and epidemiology of prostate carcinoma;Ruijter;Endocr Rev,1999

4. Growth factors involved in prostate carcinogenesis;Kambhampati;Front Biasci,2005

5. Neuroendocrine differentiation in prostatic carcinoma;Di Sant’Agnese;Prostate,1998

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FSH, bone, belly and brain;Journal of Endocrinology;2024-04-03

2. Are higher follicle-stimulating hormone levels before androgen deprivation therapy for prostate cancer associated with oncological and cardiac outcomes and overall survival?—a population-level analysis;Translational Andrology and Urology;2023-10

3. Extra-Gonadal and Non-Canonical Effects of FSH in Males;Pharmaceuticals;2023-05-30

4. A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy;JCI Insight;2022-11-22

5. Should LHRH therapy be continued in patients receiving abiraterone acetate?;Prostate Cancer and Prostatic Diseases;2022-08-26